Wnt/β-catenin信号通路在肿瘤耐药中的研究进展

国际肿瘤学杂志››2016,Vol. 43››Issue (6): 455-457.doi:10.3760/cma.j.issn.1673-422X.2016.06.015

Wnt/β-catenin信号通路在肿瘤耐药中的研究进展

移志刚，周开升，蒲彦川，王兴文，王拴科

730030 兰州大学第二医院骨科

收稿日期:2015-08-03出版日期:2016-06-08发布日期:2016-04-27
通讯作者:王拴科 E-mail:wsk2zzy@yahoo.com.cn
基金资助:

甘肃省创新研究群体计划（1308RJIA004）

Research progress of Wnt/β-catenin signaling pathway in tumor drug resistance

Yi Zhigang, Zhou Kaisheng, Pu Yanchuan, Wang Xingwen, Wang Shuanke

Department of Orthopaedics, Second Hospital of Lanzhou University, Lanzhou 730030, China

Received:2015-08-03Online:2016-06-08Published:2016-04-27
Contact:Wang Shuanke E-mail:wsk2zzy@yahoo.com.cn
Supported by:

Innovative Research Group Project of Gansu Province (1308RJIA004)

摘要/Abstract

摘要：Wnt/β-catenin信号通路参与肿瘤细胞的增殖、侵袭和转移，并且诱导肿瘤的耐药，是介导组织癌变的关键通路。体外实验表明，靶向抑制Wnt/β-catenin能够增强化疗药物的敏感性。因此对Wnt/β-catenin介导肿瘤耐药的深入研究将为肿瘤的治疗提供可能途径和潜在靶点。

移志刚，周开升，蒲彦川，王兴文，王拴科. Wnt/β-catenin信号通路在肿瘤耐药中的研究进展[J]. 国际肿瘤学杂志, 2016, 43(6): 455-457.

Yi Zhigang, Zhou Kaisheng, Pu Yanchuan, Wang Xingwen, Wang Shuanke. Research progress of Wnt/β-catenin signaling pathway in tumor drug resistance[J]. Journal of International Oncology, 2016, 43(6): 455-457.

参考文献

［1］Liu YY, Gupta V, Patwardhan GA, et al. Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling[J]. Mol Cancer, 2010, 9: 145. DOI: 10.1186/1476-4598-9-145. ［2］ Gan SY, Zhong XY, Xie SM, et al. Expression and significance of tumor drug resistance related proteins and betacatenin in esophageal squamous cell carcinoma［J］. Chin J Cancer, 2010, 29(3): 300-305. ［3］ Nusse R, Varmus HE. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome［J］. Cell, 1982, 31(1): 99-109. ［4］ Rijsewijk F, Schuermann M, Wagenaar E, et al. The drosophila homolog of the mouse mammary oncogene int1 is identical to the segment polarity gene wingless［J］. Cell, 1987, 50(4): 649-657. ［5］ Akiyama T. Wnt/betacatenin signaling［J］. Cytokine Growth Factor Rev, 2000, 11(4): 273-282. ［6］ Thomas DW. Bone and cancer［J］. J Pathol, 2010, 220(1): 1-4. ［7］ Ma Y, Ren Y, Han EQ, et al. Inhibition of the Wntβcatenin and Notch signaling pathways sensitizes osteosarcoma cells to chemotherapy［J］. Biochem Biophys Res Commun, 2013, 431(2): 274-279. DOI: 10.1016/j.bbrc.2012.12.118. ［8］ Zhang F, Chen A, Chen J, et al. SiRNAmediated silencing of betacatenin suppresses invasion and chemosensitivity to doxorubicin in MG63 osteosarcoma cells［J］. Asian Pac J Cancer Prev, 2011, 12(1): 239-245. ［9］ Zhang F, Chen A, Chen J, et al. Influence of βcatenin small interfering RNA on human osteosarcoma cells［J］. J Huazhong Univ Sci Technolog Med Sci, 2011, 31(3): 353-358. DOI: 10.1007/s11596-011-0380-9. ［10］ Morin PJ. Betacatenin signaling and cancer［J］. Bioessays, 1999, 21(12): 1021-1030. ［11］ Wang X, Wu X, Wang C, et al. Transcriptional suppression of breast cancer resistance protein (BCRP) by wildtype p53 through the NFkappaB pathway in MCF7 cells［J］. FEBS Lett, 2010, 584(15): 33923397. DOI: 10.1016/j.febslet.2010.06.033. ［12］ Zhang H, Zhang X, Wu X, et al. Interference of frizzled 1 (FZD1) reverses multidrug resistance in breast cancer cells through the Wnt/βcatenin pathway［J］. Cancer Lett, 2012, 323(1): 106-113. DOI: 10.1016/j.canlet.2012.03.039. ［13］ Kildal W, Risberg B, Abeler VM, et al. Betacatenin expression, DNA ploidy and clinicopathological features in ovarian cancer: a study in 253 patients［J］. Eur J Cancer, 2005, 41(8): 1127-1134. DOI: 10.1016/j.ejca.2005.01.022. ［14］ Cai G, Wang J, Xin X, et al. Phosphorylation of glycogen synthase kinase3 beta at serine 9 confers cisplatin resistance in ovarian cancer cells［J］. Int J Oncol, 2007, 31(3): 657-662. ［15］ Zhao H, Wei W, Sun Y, et al. Interference with the expression of βcatenin reverses cisplatin resistance in A2780/DDP cells and inhibits the progression of ovarian cancer in mouse model［J］. DNA Cell Biol, 2015, 34(1): 55-62. DOI: 10.1089/dna.2014.2626. ［16］ He B, Barg RN, You L, et al. Wnt signaling in stem cells and nonsmallcell lung cancer［J］. Clin Lung Cancer, 2005, 7(1): 54-60. DOI: 10.3816/CLC.2005.n.022. ［17］ Gao Y, Liu Z, Zhang X, et al. Inhibition of cytoplasmic GSK3β increases cisplatin resistance through activation of Wnt/βcatenin signaling in A549/DDP cells［J］. Cancer Lett, 2013, 336(1): 231-239. DOI: 10.1016/j.canlet.2013.05.005. ［18］ Cheng H, Liang H, Qin Y, et al. Nuclear betacatenin overexpression in metastatic sentinel lymph node is associated with synchronous liver metastasis in colorectal cancer［J］. Diagn Pathol, 2011, 6: 109. DOI: 10.1186/1746-1596-6-109. ［19］万兵, 郑玉仙, 叶飞君. Wnt/βcatenin信号通路在肝癌耐药中的研究作用［J］. 中国综合临床, 2012, 28(12): 1242-1245. DOI: 10.3760/cma.j.issn.10086315.2012.12.004. ［20］ Xu N, Shen C, Luo Y, et al. Upregulated miR130a increases drug resistance by regulating RUNX3 and Wnt signaling in cisplatintreated HCC cell［J］. Biochem Biophys Res Commun, 2012, 425(2): 468-472. DOI: 10.1016/j.bbrc.2012.07.127. ［21］ Shen DY, Zhang W, Zeng X, et al. Inhibition of Wnt/β-catenin signaling downregulates P-glycoprotein and reverses multidrug resistance of cholangiocarcinoma［J］. Cancer Sci, 2013, 104(10): 1303-1308. DOI: 10.1111/cas.12223. ［22］ Shen DY, Kang JH, Song W, et al. Apoptosis of human cholangiocarcinoma cell lines induced by β-escin through mitochondrial caspasedependent pathway［J］. Phytother Res, 2011, 25(10): 1519-1526. DOI: 10.1002/ptr.3435. ［23］ Huang GL, Shen DY, Cai CF, et al. βescin reverses multidrug resistance through inhibition of the GSK3β/βcatenin pathway in cholangiocarcinoma［J］. World J Gastroenterol, 2015, 21(4): 1148-1157. DOI: 10.3748/wjg.v21.i4.1148.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲.血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊.局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华.Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青.血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺.PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云.新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚.EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵.抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六.基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六.肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东.ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅.基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳.炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝.癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志.宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.